SBIR/STTR Research Award

Attenuation of Radiation-Induced GI Injury by Cultured Myeloid Progenitors

Award identifier dd5c2c6da93e14d721bed20610c9a09b5448ec435e316ec239cd62dd89e37de4Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$300,000

Program and phase

STTR · Phase I

Award year

2007

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Cellerant Therapeutics, Inc.
Proposal award date
Not reported
Contract end date
Not reported
UEI
LML1YE6L8KU3
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): Our long term goal is to develop a universal cell-based therapy containing human myeloid progenitor cells to attenuate radiation-induced gastrointestinal or hematopoietic injury. Radiation (XRT) remains an important therapeutic modality in the treatment of malignancies. Injury to the gastrointestinal tract (GI) and hematopoietic system are serious sequelae of radiation exposure for which there are few effective post-exposure therapies. Direct cellular disruption, upregulation of chemokine/cytokine production, microbial invasion in the setting of impaired innate immunity and coagulation all contribute to XRT-induced gastrointestinal (GI) injury. We postulate that the repletion of the myeloid/megakaryocyte progenitor pools will protect against XRT-induced injury by the replacement of hematopoietic precursors and immunomodulation of the gastrointestinal mucosa. These progenitors are well- characterized, short-lived, subpopulations collectively referred to as myeloid progenitors that give rise to granulocytes, macrophages, dendritic cells, erythrocytes and platelets. We have refined ex-vivo culture conditions resulting in the successful expansion and cryopreservation of these myeloid progenitor cells (MPc). The rationale for our hypothesis has been established by our preclinical models of myeloablative radiation injury in which we have demonstrated that a single infusion of allogeneic MPc protects against a subsequent challenge with an otherwise lethal dose of Aspergillus fumigatus or pseudomonas aeruginosa. Furthermore, we have also demonstrated in preliminary studies attenuation of histologic changes in the gastrointestinal tract and protection against death following higher doses of irradiation. Medical application of radiation as a therapy for malignancies or as a preparative regimen for hematopoietic cell transplantation is often accompanied by the severe consequence of gastrointestinal (GI) injury. Our unexpected finding that allogeneic, culture-derived myeloid progenitor cells protect against radiation-induced GI injury will have a significant positive impact on the survival and quality of life of this population. The availability of a safe and effective, "off-the-shelf" treatment will also have a significant positive impact on the ability of local and federal governments to respond to mass casualties as a result of a nuclear power plant accident, terrorist detonation, or other localized radiological disasters.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

10 SBIR/STTR records share this UEI (2003–2018). Reported award amounts total $6,779,434. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.